A few tidbits on the wires yesterday about new pharma facilities. Firstly, GE and iBio announced they are designing a new plant-cell based vaccine facility for a client pharma company. The identity of the client was not disclosed. However, iBio's own SEC filing shows that Brazil's Fiocruz/Bio-Manguinhosin is the only company who has a license at present to use iBio's plant cell based platform for vaccine work.
The iBioLaunch platform is touted by its promoters to have the potential to manufacture proteins that cannot be made in other systems, and could also significantly reduce the capital and operating costs associated with biotherapeutic production.
CMC announced that it will be buying Xoma's manufacturing facility in Berkeley, CA. The facility has 31,000 sq ft of space and 3 x 2750 L bioreactors. CMC also has facilities in Denmark and Bothell, WA (acquired from Icos) to serve the biopharm industry. A CMC spokesman said that acquisition of a new facility in the Bay area was a big plus as many new start up companies are there in need of manufacturing help. The new facility doubles CMC's US capacity. See Xconomy.
Covidien has officially cut the ribbon on its new $45 million R&D facility in Shanghai, where it plans to employ more than 300 in new research efforts. Covidien is just one of the latest western companies to open a new facility in China.
"China is a key market in our global strategy, and this investment is a reflection of our strategic initiatives," said Covidien CEO José E. Almeida in a statement. And Covidien--a device and pharma developer--boasted that the operation covers more than 100,000 square feet with 17 labs and surgical and simulation suites. See Fierce Biotech.
Posted by Bruce Lehr Aug 2nd 2012.